






Contractor Details	Type/ size of legal entity	Place of performance of contract activities	Logo
<p><u>Main contractor</u></p> <p>FUNDACIO CENTRE DE REGULACIO GENOMICA PRBB Building, Dr Aiguader 88 08003 Barcelona, SPAIN MONICA BAYES monica.bayes@cnag.crg.eu</p>	Research institute	<p>% of contract value allocated to main contractor: 92.64 %</p> <p>% of activities for the contract performed by the main contractor in EU Member States or countries associated with Horizon 2020: 100 %</p>	
<p><u>Subcontractors (if applicable)</u></p> <p>1. TECNO-MED INGENIEROS, S.L. Marie Curie 8, 08042, Barcelona, SPAIN XAVIER CANALS RIERA Phone nr contact person xcanals@tecno-med.es</p>	SME	<p>% of contract value allocated to subcontractor [1]: 2.28%</p> <p>% of activities for the contract performed by subcontractor [1] in EU Member States or countries associated with Horizon 2020: 100 %</p>	
<p>2. GENESIS Biomed SL . Parc Científic de Barcelona, Baldri Reixac 4-8, 08028 Barcelona, SPAIN Josep Lluís Falcó josep.lluis.falco@genesis-biomed.com</p>	SME	<p>% of contract value allocated to subcontractor [2]: 1.88 %</p> <p>% of activities for the contract performed by subcontractor [2] in EU Member States or countries associated with Horizon 2020: 100 %</p>	
<p>3. Internet Security Auditors, S.L. Santander 101 (Edificio A. 2º), 08030 Barcelona, SPAIN Antoni Nicolás anicolas@isecauditors.com</p>	SME	<p>% of contract value allocated to subcontractor [3]: 1.17 %</p> <p>% of activities for the contract performed by subcontractor [3] in EU Member States or countries associated with Horizon 2020: 100 %</p>	
<p>4. Fundación Instituto de Investigación Oncológica Vall d'Hebron CENTRO CELLEX, Natzaret 115-117, 08035 Barcelona, SPAIN Carlos López clopez@vhio.net</p>	Research institute	<p>% of contract value allocated to subcontractor [3]: 2.03 %</p> <p>% of activities for the contract performed by subcontractor [3] in EU Member States or countries associated with Horizon 2020: 100 %</p>	

Project abstract

The Cancer Reporting GPAP will be a user-friendly solution integrating next generation sequencing (NGS) results, e-medication data and clinical evidence for therapy decision making in adult and paediatric cancers, common and rare. The system will enable user-friendly interpretation and pathogenicity ranking of the NGS variants, according to ACMG/AMP/ASCO/CAP guidelines, using functional and medical annotations through external resources and the Cancer Genome Interpreter (CGI). The clinical reporting module will support off-line consultation for optimal bedside use. The reports will be translated into at least 3 languages. The system will be based on the current RD-Connect

Genome-Phenome Analysis Platform, developed upon a big data architecture and a user-friendly graphical user interface, accessible through a web browser. Security will be incorporated in all the stages of the Software Development Life Cycle considering the EU GDPR and relevant ISO and IVDR requirements.

Previous EU funding

Is the project based on / a continuation of R&D activities that were previously funded by the EU?: YES
If yes, identify this EU funding:

FP7-HEALTH-2012-INNOVATION-1, RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research, GA 305444

H2020-SC1-2016-2017, Solving the unsolved Rare Diseases, GA 779257

H2020-SC1-BHC-2018-2020, European Joint Programme on Rare Diseases, GA 825575



Project funded by the EU Horizon 2020 Programme

